Infectious Disease Screening and Detection
Infectious disease screening is the systematic application of tests to people without recognised symptoms in order to identify those who carry or are infected by a transmissible pathogen, so that infection can be detected at an early or latent stage. As a form of secondary prevention it aims both to benefit the individual through earlier treatment and to interrupt onward transmission in the population.
Definition
Infectious disease screening is the use of a test or examination to detect asymptomatic or latent infection in defined populations, classified as secondary prevention because it seeks to identify and act on disease before it becomes clinically apparent.
Scope
This area orients the reader to screening for communicable infections in primary care and public health settings. It groups the major screening domains covered by its child topics — sexually transmitted infections, tuberculosis, and bloodborne pathogens such as HIV and the hepatitis viruses — and frames the shared logic of test selection, target populations, and the dual individual-and-population purpose of infection screening. It is a reference overview and does not provide individualised testing or treatment instructions.
Sub-topics
Core questions
- Which infections meet the criteria that justify population screening rather than testing only symptomatic individuals?
- How are target populations and screening intervals defined for a given pathogen?
- What distinguishes a screening test from a confirmatory or diagnostic test in the detection pathway?
- How does screening serve both individual benefit and interruption of transmission?
Key concepts
- Secondary prevention
- Asymptomatic and latent infection
- Screening versus confirmatory testing
- Target population and risk-based screening
- Sensitivity and specificity of screening tests
- Interruption of transmission
- Wilson and Jungner screening criteria
Mechanisms
Infection screening rests on the existence of a detectable preclinical phase — a period during which a pathogen, its antigens, its nucleic acid, or the host immune response to it can be identified before symptoms appear. A screening test is applied to an at-risk but asymptomatic population; reactive results are then confirmed with a more specific test before a diagnosis is assigned. Because many transmissible infections (for example HIV, chronic hepatitis B and C, latent tuberculosis, and several sexually transmitted infections) can remain silent for long periods while still being transmissible or progressing to organ damage, detecting them early can both improve individual outcomes and reduce spread. The classic Wilson and Jungner principles set out the conditions under which such screening is justified.
Clinical relevance
Screening programmes for infectious diseases shape how primary-care and public-health services identify infections that would otherwise go unrecognised, and understanding their rationale supports critical appraisal of screening recommendations. This entry describes how infection screening is conceived and evaluated as a preventive activity; it is not a protocol for whom to test or how to manage a positive result, which are governed by current clinical guidelines.
Epidemiology
The burden addressed by infection screening is substantial: HIV, the viral hepatitides, tuberculosis, and the common sexually transmitted infections together account for a large share of global communicable-disease morbidity, and a sizeable fraction of those infected are unaware of their status. National task forces and public-health agencies therefore define risk-based or universal screening for these infections, and the specific epidemiology and recommendations are detailed in the child topics.
History
Systematic screening for infection grew out of twentieth-century public-health programmes — notably mass radiographic and tuberculin testing for tuberculosis and serologic testing for syphilis. The 1968 World Health Organization monograph by Wilson and Jungner provided the enduring framework of criteria for when screening is worthwhile, and later expansions in serology and nucleic-acid amplification testing extended screening to HIV, the hepatitis viruses, and a widening range of sexually transmitted infections.
Key figures
- James Maxwell Glover Wilson
- Gunnar Jungner
- Madhukar Pai
Related topics
Seminal works
- wilson-jungner-1968
- uspstf-hiv-2019
Frequently asked questions
- Why screen people who have no symptoms for an infection?
- Many transmissible infections have a long asymptomatic or latent phase during which they can still be passed on or cause silent damage; detecting them early can allow treatment before symptoms develop and can reduce onward transmission.
- Is a positive screening test the same as a diagnosis?
- No. Screening tests are designed to be sensitive and to flag people who may be infected; a reactive screening result is normally confirmed with a more specific diagnostic test before an infection is diagnosed.